Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current pharmaceutical design

• Publication date

  2007-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138161207780618966PMID 17430175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of VIP gene expression in general

  2007cited by this paper
• Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro

  2007cited by this paper
• Regulation of immune tolerance by anti-inflammatory neuropeptides

  2007cited by this paper
• The role of HLA promoters in autoimmunity.

  2006cited by this paper
• Blood-brain barrier transport of cytokines: a mechanism for neuropathology.

  2005cited by this paper
• Neural and behavioral responses to systemic immunologic stimuli: a consideration of bacterial T cell superantigens.

  2005cited by this paper
• Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: Transduction of both Ca2+ and cyclic AMP signals

  2005cited by this paper
• Chemokines in rheumatoid arthritis

  2004cited by this paper
• VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells

  2004cited by this paper
• Pituitary adenylate cyclase‐activating polypeptide inhibits cutaneous immune function

  2003cited by this paper
• Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis.

  2003cited by this paper
• The neuropeptides VIP/PACAP and T cells: inhibitors or activators?

  2003cited by this paper
• Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity.

  2003cited by this paper
• Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

  2003cited by this paper
• VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools.

  2003cited by this paper
• Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration.

  2003cited by this paper
• Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma

  2003cited by this paper
• Neuroinflammatory processes in Parkinson's disease

  2003cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit the production of inflammatory mediators by activated microglia

  2003cited by this paper
• Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation

  2003cited by this paper
• Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma

  2003cited by this paper
• The state of the art in the management of inflammatory bowel disease.

  2003cited by this paper
• Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.

  2003cited by this paper
• PACAP in Immunity and Inflammation

  2003cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.

  2003cited by this paper
• The Role of Glial Reaction and Inflammation in Parkinson's Disease

  2003cited by this paper
• Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression.

  2003cited by this paper
• Passage of vasoactive intestinal peptide across the blood-brain barrier.

  2003cited by this paper
• Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice1

  2003cited by this paper
• VIP and PACAP are autocrine factors that protect the androgen‐independent prostate cancer cell line PC‐3 from apoptosis induced by serum withdrawal

  2003cited by this paper
• Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

  2003cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1alpha production and mRNA expression.

  2002cited by this paper
• Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis.

  2002cited by this paper
• The role of Th1/Th2 polarization in mucosal immunity

  2002cited by this paper
• Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10.

  2002cited by this paper
• Direct and Indirect Inhibition of Th1 Development by Progesterone and Glucocorticoids1

  2002cited by this paper
• Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.

  2002cited by this paper
• PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways.

  2002cited by this paper
• Vasoactive intestinal peptide attenuates cytochrome c translocation, and apoptosis, in rat hippocampal stem cells.

  2002cited by this paper
• A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.

  2002cited by this paper
• Pituitary Adenylate-Cyclase-Activating Polypeptide Expression in the Immune System

  2002cited by this paper
• Catecholamines Inhibit the Antigen-Presenting Capability of Epidermal Langerhans Cells1

  2002cited by this paper
• BLOCKING THE CD80 AND CD86 COSTIMULATION MOLECULES: LESSONS TO BE LEARNED FROM ANIMAL MODELS

  2002cited by this paper
• Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor

  2002cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microglia

  2002cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia.

  2002cited by this paper
• The role of glial cells in Parkinson's disease

  2001cited by this paper
• Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor

  2001cited by this paper
• Prospects for research in inflammatory bowel disease.

  2001cited by this paper
• Inhibition of Endotoxin-Induced Macrophage Chemokine Production by VIP and PACAP In Vitro and In Vivo

  2001cited by this paper
• Alpha-synuclein and neurodegenerative diseases

  2001cited by this paper
• Inhibitory neuropeptide receptors on macrophages.

  2001cited by this paper
• Family-B G-protein-coupled receptors

  2001cited by this paper
• Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells1

  2001cited by this paper
• Vasoactive intestinal polypeptide as mediator of asthma.

  2001cited by this paper
• Neuroprotective peptide drug delivery and development: potential new therapeutics.

  2001cited by this paper
• VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells.

  2001cited by this paper
• Inhibition of Endotoxin-Induced Macrophage Chemokine Production by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide In Vitro and In Vivo1

  2001cited by this paper
• Pituitary adenylate cyclase-activating peptide inhibits neutrophil chemotaxis

  2001cited by this paper
• Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide

  2001cited by this paper
• Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

  2001cited by this paper
• Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases

  2001cited by this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Collagen-Induced Arthritis: An Experimental Immunomodulatory Therapy1

  2001cited by this paper
• Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine?

  2001cited by this paper
• The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety

  2001cited by this paper
• Mechanisms in failure of infliximab for Crohn's disease.

  2000cited by this paper
• Anti‐inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock

  2000cited by this paper
• Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit T Cell-Mediated Cytotoxicity by Inhibiting Fas Ligand Expression1

  2000cited by this paper
• IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1

  2000cited by this paper
• New insights into the pathogenesis of rheumatoid arthritis.

  2000cited by this paper
• MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies

  2000cited by this paper
• Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo

  2000cited by this paper
• IL‐4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis

  2000cited by this paper
• Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

  2000cited by this paper
• Receptors and Transcriptional Factors Involved in the Anti‐Inflammatory Activity of VIP and PACAP

  2000cited by this paper
• Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide.

  2000cited by this paper
• Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Antigen-Induced Apoptosis of Mature T Lymphocytes by Inhibiting Fas Ligand Expression1

  2000cited by this paper
• Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

  2000cited by this paper
• Somatostatin and Substance P Induced in vivo by Lipopolysaccharide and in Peritoneal Macrophages Stimulated with Lipopolysaccharide or Interferon-Gamma Have Differential Effects on Murine Cytokine Production

  2000cited by this paper
• Apoptosis modulators in the therapy of neurodegenerative diseases

  2000cited by this paper
• Immunology of VIP: a review and therapeutical perspectives.

  2000cited by this paper
• Does the failure to acquire helminthic parasites predispose to Crohn's disease?

  2000cited by this paper
• A new concept in the pharmacology of neuroprotection

  2000cited by this paper
• Pathogenesis of bone erosions in rheumatoid arthritis

  2000cited by this paper
• Leukocyte activation and cytokine production during experimental human endotoxemia.

  2000cited by this paper
• In vitro and in vivo regulation of chemokine receptors.

  2000cited by this paper
• Vasoactive Intestinal Peptide and Pituitary Adenylyl Cyclase-Activating Polypeptide Inhibit Tumor Necrosis Factor-α Production in Injured Spinal Cord and in Activated Microglia via a cAMP-Dependent Pathway

  2000cited by this paper
• VIP and PACAP Induce Shift to a Th2 Response by Upregulating B7.2 Expression

  2000cited by this paper
• Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat.

  2000cited by this paper
• Neuroprotective Effects of PACAP38 in a Rat Model of Transient Focal Ischemia under Various Experimental Conditions

  2000cited by this paper
• VPAC1 Receptors and Lung Cancer

  2000cited by this paper
• New and future drug therapies for rheumatoid arthritis.

  2000cited by this paper
• Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock.

  2000cited by this paper
• Immunobiology of vasoactive intestinal peptide (VIP)

  2000cited by this paper
• The Role of IL-10 in Inflammatory Bowel Disease: "Of Mice and Men"

  1999cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.

  1999cited by this paper
• Altered memory T cell differentiation in patients with early rheumatoid arthritis.

  1999cited by this paper
• Interleukin-6 and transforming growth factor-beta regulate the expression of monocyte chemoattractant protein-1 and colony-stimulating factors in human thyroid follicular cells.

  1999cited by this paper
• Immunopathologic Alterations in Murine Models of Sepsis of Increasing Severity

  1999cited by this paper
• Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives.

  1999cited by this paper

• Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy—Shedding of ACE2 and TMPRSS2 via ADAM10

  2025cites this paper
• Visual stimulation and brain-derived neurotrophic factor (BDNF) have protective effects in experimental autoimmune uveoretinitis.

  2024cites this paper
• Developmental drugs for sarcoidosis.

  2024cites this paper
• Signal Transduction by VIP and PACAP Receptors

  2022cites this paper
• Dysregulation of Multiple Signaling Neurodevelopmental Pathways during Embryogenesis: A Possible Cause of Autism Spectrum Disorder

  2021cites this paper
• Protective effects of VIP and PACAP in SARS-CoV-2 infection

  2021cites this paper
• The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease the production of proinflammatory cytokines, and VIP levels are associated with survival in severe COVID-19 patients

  2021cites this paper
• Neurochemistry of Enteric Neurons Following Prolonged Indomethacin Administration in the Porcine Duodenum

  2020cites this paper
• VIP plasma levels associate with survival in severe COVID‐19 patients, correlating with protective effects in SARS‐CoV‐2‐infected cells

  2020cites this paper
• The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells

  2020cites this paper
• Protective Effects of PACAP in Peripheral Organs

  2020cites this paper
• Vasoactive intestinal peptide inhibits the activation of murine fibroblasts and expression of interleukin 17 receptor C

  2019cites this paper
• 23 Vasoactive Neuropeptides in Autoimmune Diseases

  2018cites this paper
• Why are Behçet's disease patients always exhausted?

  2018cites this paper
• The Neuropeptides Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Control HIV-1 Infection in Macrophages Through Activation of Protein Kinases A and C

  2018cites this paper
• Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: findings from the pregnancy and childhood epigenetics (PACE) consortium

  2017cites this paper
• Cardiovascular, inflammatory and circadian aspects of metabolic regulation in humans

  2017cites this paper
• Evaluation of Immune-Modulating Therapies For Parkinson's Disease

  2017cites this paper
• Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function

  2016cites this paper
• PACAP Regulation of Inflammatory and Free Radical Networks in Neuronal and Nonneuronal Diseases

  2016cites this paper
• The Role of Dendritic Cells in Central Nervous System Autoimmunity: Focusing on Multiple Sclerosis and Emerging Therapeutics Targeting Dendritic Cells

  2016cites this paper
• PACAP suppresses dry eye signs by stimulating tear secretion

  2016cites this paper
• Therapeutic Potential of Foldamers: From Chemical Biology Tools To Drug Candidates?

  2016cites this paper
• The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study.

  2016cites this paper
• Arthritis and cholinergic transition of sympathetic nerve fibers

  2016influential citation
• The Decrease of Dendritic Cells Activation by “PAMPS” and Peripheral Blood Mononuclear Cells Activation by “DAMPS” Danger Signals in Presence of VIP Neuropeptide

  2016cites this paper
• Electroacupuncture Attenuates Collagen-Induced Arthritis in Rats through Vasoactive Intestinal Peptide Signalling-Dependent Re-Establishment of the Regulatory T Cell/T-Helper 17 Cell Balance

  2015cites this paper
• Viral and bacterial septicaemic infections modulate the expression of PACAP splicing variants and VIP/PACAP receptors in brown trout immune organs.

  2015cites this paper
• Vasoactive intestinal peptide suppresses macrophage‐mediated inflammation by downregulating interleukin‐17A expression via PKA‐ and PKC‐dependent pathways

  2015cites this paper
• egulation of nutrition-associated receptors in blood monocytes of ormal weight and obese humans

  2015cites this paper
• Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice

  2015cites this paper
• The Effects of Endocannabinoid Modulation and Neurogenic Inflammation in Experimental Knee Joint Arthritis

  2015cites this paper
• VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

  2015cites this paper
• Neuronal pathways in tendon healing and tendinopathy--update.

  2014cites this paper
• Single Nucleotide Polymorphisms in the 3′UTR of VPAC-1 Cooperate in Modulating Gene Expression and Impact Differently on the Interaction with miR525-5p

  2014cites this paper
• Microglial VPAC1R mediates a novel mechanism of neuroimmune-modulation of hippocampal precursor cells via IL-4 release

  2014cites this paper
• Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance.

  2014cites this paper
• Peptide therapeutics in neurodegenerative disorders.

  2014cites this paper
• VIP (vasoactive intestinal peptide)

  2014cites this paper
• An imbalance between substance P and vasoactive intestinal polypeptide might contribute to the immunopathology of megaesophagus after Trypanosoma cruzi infection.

  2013cites this paper
• Development of therapeutics for the treatment of diabetic brain complications

  2013cites this paper
• Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice.

  2013cites this paper
• Macrophage Resistance to HIV-1 Infection Is Enhanced by the Neuropeptides VIP and PACAP

  2013cites this paper
• The Gut's Little Brain in Control of Intestinal Immunity

  2013cites this paper
• Emerging neuropeptide targets in inflammation: NPY and VIP.

  2013cites this paper
• The Gut's Little Brain in Control of Intestinal Immunity.

  2013cites this paper
• PACAP : a novel neuropeptide for pituitary gonadotroph maturation, function and regulation.

  2013cites this paper
• Improvement of drug safety by the use of lipid-based nanocarriers.

  2012cites this paper
• Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1.

  2012cites this paper
• Vasoactive neuropeptides in autoimmune diseases

  2011cites this paper
• Guide to Receptors and Channels (GRAC), 5th edition

  2011cites this paper
• Neuropeptides as Pleiotropic Modulators of the Immune Response

  2011cites this paper
• Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.

  2011cites this paper
• Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1

  2011cites this paper
• VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies

  2011cites this paper
• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis

  2011cites this paper
• Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

  2011cites this paper
• Explorer Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription coactivator 1

  2011cites this paper
• Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice.

  2011cites this paper
• Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

  2010cites this paper
• Novel pathomechanisms in chronic fatigue syndrome/myalgic encephalomyelitis: do purinergic signalling perturbations and gliosis play a role?

  2010cites this paper
• Sudden infant death syndrome: Postulated role of impaired vasoactive neuropeptide-related inflammatory modulation

  2010cites this paper
• Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons

  2010cites this paper
• Neuropeptides as therapeutic approach to autoimmune diseases.

  2010cites this paper
• Efeito do peptídeo liberador de gastrina na resposta inflamatória local e sistêmica : envolvimento na sinalização do receptor Toll-like 4

  2010influential citation
• Host‐bacteria interactions in the intestine: homeostasis to chronic inflammation

  2010cites this paper
• Computational studies of the folding patterns of small and medium-size polypeptides

  2010cites this paper
• Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.

  2010cites this paper
• Molecular dynamics (MD) simulations of VIP and PACAP27

  2009cites this paper
• 7TM RECEPTORS

  2009cites this paper
• Neuronal pathways in tendon healing.

  2009cites this paper
• Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats.

  2009cites this paper
• Guide to Receptors and Channels (GRAC), 4th edition

  2009cites this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cites this paper
• Apoptosis in the homeostasis of the immune system and in human immune mediated diseases.

  2008cites this paper
• Role of PACAP in Ischemic Neural Death

  2008cites this paper
• Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders

  2008cites this paper
• The epidemiology of sepsis.

  2008cites this paper
• Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

  2008cites this paper
• Postulated vasoactive neuropeptide immunopathology affecting the blood–brain/blood–spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?

  2008cites this paper
• The role of neuromediators in ocular allergy

  2008cites this paper
• 7TM Receptors

  2008cites this paper
• Effects of vasoactive intestinal peptide on phenotypic and functional maturation of dendritic cells.

  2008cites this paper
• Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis.

  2008cites this paper
• The role of heme oxygenase-1 in T cell-mediated immunity: the all encompassing enzyme.

  2008cites this paper
• Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells.

  2008cites this paper
• Role of neuropeptides in migraine: where do they stand in the latest expert recommendations in migraine treatment?

  2007cites this paper